Genmab AS (GMAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genmab AS (GMAB) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($300.34 Million) by net assets ($5.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Genmab AS (GMAB) total market value for the company's overall valuation and market capitalisation.
Genmab AS - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Genmab AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genmab AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genmab AS ranked by their cash flow conversion efficiency. Explore cash flow quality index of Genmab AS to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Century Huatong Group Co Ltd
SHE:002602
|
0.079x |
|
Zangge Holding Co Ltd
SHE:000408
|
0.044x |
|
Korea Shipbuilding & Offshore Engineering Co Ltd
KO:009540
|
0.103x |
|
Leidos Holdings Inc
NYSE:LDOS
|
0.059x |
|
James Hardie Industries Plc
AU:JHX
|
0.031x |
|
Annaly Capital Management, Inc.
NYSE:NLY
|
0.095x |
|
Fuyao Glass Industry Group Co Ltd Class A
SHG:600660
|
0.065x |
|
Banco de Sabadell S.A
MC:SAB
|
0.018x |
Annual Cash Flow Conversion Efficiency for Genmab AS (2002–2025)
The table below shows the annual cash flow conversion efficiency of Genmab AS from 2002 to 2025. View Genmab AS share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.83 Billion | $1.19 Billion | 0.203x | -3.92% |
| 2024-12-31 | $36.70 Billion | $7.77 Billion | 0.212x | -9.30% |
| 2023-12-31 | $31.61 Billion | $7.38 Billion | 0.233x | +62.82% |
| 2022-12-31 | $27.28 Billion | $3.91 Billion | 0.143x | +42.85% |
| 2021-12-31 | $22.20 Billion | $2.23 Billion | 0.100x | -70.16% |
| 2020-12-31 | $19.12 Billion | $6.43 Billion | 0.336x | +256.43% |
| 2019-12-31 | $14.05 Billion | $1.33 Billion | 0.094x | -25.45% |
| 2018-12-31 | $8.01 Billion | $1.01 Billion | 0.127x | -50.02% |
| 2017-12-31 | $6.27 Billion | $1.59 Billion | 0.253x | +273.12% |
| 2016-12-31 | $4.83 Billion | $327.72 Million | 0.068x | -23.99% |
| 2015-12-31 | $3.49 Billion | $311.45 Million | 0.089x | +36.87% |
| 2014-12-31 | $2.03 Billion | $132.67 Million | 0.065x | +133.63% |
| 2013-12-31 | $659.52 Million | $-128.00 Million | -0.194x | -204.86% |
| 2012-12-31 | $383.19 Million | $70.92 Million | 0.185x | +120.59% |
| 2011-12-31 | $486.42 Million | $-437.23 Million | -0.899x | -462.02% |
| 2010-12-31 | $1.08 Billion | $268.17 Million | 0.248x | +156.50% |
| 2009-12-31 | $1.30 Billion | $-570.06 Million | -0.439x | -87.36% |
| 2008-12-31 | $2.19 Billion | $-513.33 Million | -0.235x | -233.68% |
| 2007-12-31 | $2.88 Billion | $505.90 Million | 0.175x | +174.30% |
| 2006-12-31 | $1.61 Billion | $-379.62 Million | -0.236x | -26.62% |
| 2005-12-31 | $1.12 Billion | $-208.64 Million | -0.186x | +40.10% |
| 2004-12-31 | $1.18 Billion | $-367.70 Million | -0.311x | -11.87% |
| 2003-12-31 | $1.09 Billion | $-302.36 Million | -0.278x | -26.30% |
| 2002-12-31 | $1.40 Billion | $-308.32 Million | -0.220x | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more